Yesterday’s Capital Markets Day highlighted the successful re-positioning of the company over the past 18 months (including a strengthening of its management and development teams) and the liver-targeted GalNac-siRNA technology platform, with a particular focus on lead programmes SLN124 and SLN226 (INDs expected Q4 2018 and Q2 2019 respectively). A particularly interesting takeaway was the sustained duration of gene knockdown achievable through GalNAc mediated siRNA delivery, which bodes well fo ....
15 Nov 2017
N+1 Singer - Silence Therapeutics - Successful Capital Markets Day highlighting the broad utility of GalNAc
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Silence Therapeutics - Successful Capital Markets Day highlighting the broad utility of GalNAc
Silence Therapeutics plc (SLNCF:OTC) | 0 0 0.0%
- Published:
15 Nov 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
Yesterday’s Capital Markets Day highlighted the successful re-positioning of the company over the past 18 months (including a strengthening of its management and development teams) and the liver-targeted GalNac-siRNA technology platform, with a particular focus on lead programmes SLN124 and SLN226 (INDs expected Q4 2018 and Q2 2019 respectively). A particularly interesting takeaway was the sustained duration of gene knockdown achievable through GalNAc mediated siRNA delivery, which bodes well fo ....